[Limitation of the disappearance of energy-rich phosphate compounds in the hyperactive atrial and ventricular myocardium by divalent Ca-antagonistic inhibitors of electromechanical coupling (iprovdratril, D 600, prenylamine)].
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D002118:Calcium / Q000037:antagonists & inhibitors; D006321:Heart / Q000187:drug effects; D006325:Heart Atria; D006352:Heart Ventricles; D009206:Myocardium / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology*; D010725:Phosphocreatine / Q000378:metabolism*; D011299:Prenylamine / Q000494:pharmacology*; D051381:Rats; D013268:Stimulation, Chemical; D014665:Vasodilator Agents / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D009570:Nitriles; D014665:Vasodilator Agents; D010725:Phosphocreatine; D000255:Adenosine Triphosphate; D014700:Verapamil; D011299:Prenylamine; D002118:Calcium
Einschränkung des Schwundes energiereicher Phosphatverbindungen im hyperaktiven Vorhofs- und Ventrikelmyokard durch Ca antagonistische Hemmstoffe der elektromechanischen Koppelung (Iproveratril, D 600, Prenylamin)